All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Maintenance Cabozantinib/Avelumab Combo Under Investigation in Metastatic Urothelial Cancer

June 18th 2022

The addition of cabozantinib to avelumab is under exploration as a maintenance approach in patients with metastatic urothelial cancer following first-line, platinum-based chemotherapy.

Repotrectinib Receives Breakthrough Therapy Designations in China for ROS1+ NSCLC

June 17th 2022

The China National Medical Products Administration’s Center for Drug Evaluation granted 2 breakthrough therapy designations to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer.

FDA Grants Fast Track Designation to Dianhydrogalactitol for Newly Diagnosed Glioblastoma

June 17th 2022

The FDA has granted a fast track designation to dianhydrogalactitol for the treatment of patients with newly-diagnosed unmethylated glioblastoma.

Fedratinib with GI Prophylaxis Has Tolerable Safety Profile in Myelofibrosis After Prior Ruxolitinib

June 17th 2022

Fedratinib was shown to be generally well tolerated in older patients with myelofibrosis who had received at least 3 months of prior ruxolitinib, according to findings from the phase 3b FREEDOM trial.

Individualized Care Informs Treatment Modality Choices in Pelvic and Sacral Ewing Carcinoma

June 17th 2022

R. Lor Randall, MD, FACS, discusses the similar benefits offered by radiation and surgery, improved surgical techniques, concerns with morbidity with each approach, and the next steps surgeons and radiation therapists can take to increase patient survival in nonmetastatic pelvic and sacral Ewing carcinoma.

Study Finds Wide Variations in Prostate Cancer Risk Within Hispanic Subgroups

June 17th 2022

Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities.

FDA Approval Sought for Momelotinib in Myelofibrosis

June 17th 2022

A new drug application seeking the approval of momelotinib for the treatment of patients with myelofibrosis has been submitted to the FDA.

Adjuvant and Neoadjuvant Treatments Chart New Course in Advanced RCC

June 17th 2022

A panel of kidney cancer experts discuss how therapeutic strategies in the neoadjuvant and adjuvant settings are affecting outcomes and how treatment selection in the first line has shifted approaches in the second and later lines of therapy.

Hormone Therapies, ADCs Elicit Long-Term Survival Benefits Across Breast Cancer Subtypes

June 17th 2022

Novel combinations with CDK4/6 inhibitors, antibody-drug conjugates, and oral selective estrogen receptor degraders are rapidly changing the treatment paradigm in hormone receptor–positive and HER2-positive breast cancer.

Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence

June 16th 2022

The peptide cancer vaccine onilcamotide failed to show superiority over placebo in terms of preventing progression in patients with prostate cancer and biochemical recurrence following curative-intent therapy, missing the primary end point of the phase 2b BRaVac trial.

Navitoclax Monotherapy Mirrors Safety of Navitoclax/Ruxolitinib, But Falls Short in Efficacy in Myelofibrosis

June 16th 2022

Single-agent navitoclax achieved a manageable safety profile compared with navitoclax plus ruxolitinib in patients with myelofibrosis. However, efficacy results, specifically at 24 weeks of treatment, favored the combination over navitoclax monotherapy.

FDA Grants Fast Track Status to PDS0101/Pembrolizumab Combo for Recurrent or Metastatic, HPV16+ Head and Neck Cancer

June 16th 2022

The FDA has granted a fast track designation to PDS0101 for use in combination with pembrolizumab in patients with recurrent or metastatic HPV16-positive head and neck cancer.

Colon Microbes Provide Clues to Favorable Treatment Options in a Subset of Colon Cancer Patients

June 16th 2022

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.

Cosibelimab Continues to Show Promise in Locally Advanced Cutaneous Squamous Cell Carcinoma

June 16th 2022

The PD-L1 antibody cosibelimab was found to elicit an encouraging objective response rate in patients with locally advanced cutaneous squamous cell carcinoma who were not eligible to undergo curative surgery or radiation.

Efforts Are Needed to Address the Enigmatic Rise of Young-Onset Gastrointestinal Cancers

June 16th 2022

Despite a steady decline in incidence and mortality rates of many cancers among older individuals in the United States and other high-income countries, an alarming rise in young-onset gastrointestinal cancers has simultaneously occurred.

Immunotherapy Combinations Contribute to Efficacy and Safety Advances in Genitourinary Cancer Treatment

June 16th 2022

New treatment strategies with immunotherapeutic agents are challenging standards of care and prolonging survival in first and later lines of metastatic urothelial carcinoma, metastatic renal cell carcinoma, and metastatic castration-resistant prostate cancer.

Quavonlimab/Pembrolizumab Combo Shows Modest Antitumor Activity in Advanced Melanoma

June 16th 2022

The combination of quavonlimab and pembrolizumab was found to be generally well tolerated and to have modest antitumor activity in patients with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor, according to data from a phase 1/2 trial (NCT03179436).

Ibrutinib Plus Venetoclax Produces High MRD Negativity Rate in Previously Untreated CLL

June 15th 2022

The addition of venetoclax to ibrutinib resulted in a high rate of minimal residual disease negativity in the blood and marrow of patients with previously untreated chronic lymphocytic leukemia.

Duvelisib and Oral Azacitidine Under Study With CHO(E)P in Peripheral T-Cell Lymphoma

June 15th 2022

Duvelisib and oral azacitidine are each being studied in combination with CHOP/CHOEP chemotherapy in patients with previously untreated CD30-negative peripheral T-cell lymphoma in the randomized phase 2 Alliance A059102 trial.

Ripretinib Does Not Provide Superior PFS Benefit Over Sunitinib in Second-line GIST, But Shows Better Tolerability

June 15th 2022

Ripretinib did not result in a significant improvement in progression-free survival over sunitinib in patients with gastrointestinal stromal tumor who were previously treated with imatinib, missing the primary end point of the phase 3 INTRIGUE trial.